Related Experiment Videos
[Fibrinolysis in acute CVA: the current status]
1Serviço de Neurologia, Hospitais da Universidade de Coimbra.
Acta Medica Portuguesa
|August 1, 1997
Summary
Thrombolytic therapy for acute ischemic stroke remains controversial. While some studies show promise with rt-PA, others using Estreptoquinase had high mortality and hemorrhage rates.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Emergency Medicine
Context:
- Thrombolytic therapy for acute ischemic stroke is a debated topic with varying clinical opinions.
- Intra-arterial thrombolysis has specific indications, but its efficacy in vertebrobasilar stroke is uncertain.
- Recent intravenous thrombolysis studies have yielded mixed results, influencing treatment guidelines.
Purpose:
- To review the current controversies and evidence surrounding thrombolytic therapy in acute ischemic stroke.
- To present the American Heart Association Guidelines for the use of recombinant tissue plasminogen activator (rt-PA) in ischemic stroke.
- To discuss the implications of successful fibrinolysis and the need for concurrent therapeutic measures.
Summary:
- Three randomized studies using Estreptoquinase (MAST-E, MAST-I, ASK) were halted due to high mortality and intracranial hemorrhage.
- Two major studies with recombinant tissue plasminogen activator (rt-PA) (ECASS and NINDS) were evaluated, with the American trial (NINDS) showing superior outcomes.
- The American Heart Association Guidelines for rt-PA use in ischemic stroke are detailed, emphasizing that successful reperfusion requires simultaneous implementation of other therapies.
Impact:
- Provides a comprehensive overview of thrombolytic therapy efficacy and safety in acute ischemic stroke.
- Informs clinical decision-making and guideline development for stroke treatment.
- Highlights the critical need for a multimodal approach to managing acute ischemic stroke patients.